✦ LIBER ✦

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours

✍ Scribed by W. Jacot; D. Bessis; E. Jorda; M. Ychou; M. Fabbro; J-L. Pujol; B. Guillot

Book ID: 108667601
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 140 KB
Volume: 151
Category: Article
ISSN: 0007-0963
DOI: 10.1111/j.1365-2133.2004.06026.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cutaneous side-effects in patients on lo

Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors

✍ A. Osio; C. Mateus; J.-C. Soria; C. Massard; D. Malka; V. Boige; B. Besse; C. Ro 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB

Effect of treatment with a colloidal oat

Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors

✍ D. T. Alexandrescu; J. G. Vaillant; C. A. Dasanu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 516 KB

Follicular and epidermal alterations in

Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor

✍ R. Van Doorn; G. Kirtschig; E. Scheffer; T.J. Stoof; G. Giaccone 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

We report the cutaneous side-effects of ZD1839 (Iressa), a new anticancer agent that acts by inhibiting epidermal growth factor (EGF) receptor signal transduction. Three patients receiving ZD1839 developed an eruption consisting of follicular papules and pustules in an acneiform distribution as well

Interstitial lung disease in patients wi

Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors

✍ Masahiro Tsuboi; Thierry Le Chevalier 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 111 KB

Ocular findings in patients with solid t

Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Phase I and II clinical trials

✍ Murray, P I; Bristow, E; Forsythe, B J; Faulkner, K; Tullo, A B; Esmaeli, B 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 187 KB

Amplification of the epidermal growth fa

Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival

✍ S. Järvellä; H. Helin; J. Haapasalo; T. Järvellä; T. T. Junttila; K. Elenius; M. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB